ABC’s recklessness could yet again put patient health at risk.

ABC’s recklessness could yet again put patient health at risk.

Opinion Piece attributable to Milton Catelin, Chief Executive, Medicines Australia.

You may be aware that the ABC has recently published and broadcast a series of reports relating to the prescription of Novel Oral Anticoagulants (NOACs) which claim doctors are being unduly influenced by innovative pharmaceutical companies to prescribe their products to patients potentially putting their health at risk.

The stories insinuate that doctors may be prescribing a NOAC product, even if it is not the right drug for their patient, simply because a pharmaceutical company provided food at a meeting or support to attend an independent medical conference. To back this assertion it used publicly available Medicines Australia reports on educational events provided transparently by our members. It also used questionable research from the United States which claims a doctor can be influenced to prescribe a particular product by as little as a sandwich from a pharmaceutical representative.

The articles rely heavily on insinuation and seek to misinform the reader about the safety of NOACs, even going so far as to tenuously link them to death.

Our strong fear is that the ABC’s reports may encourage patients to consider stopping taking their medicines when there is a high risk of potentially catastrophic outcomes for this group of patients, including stroke.

Let me be clear. Medicines Australia, and the entire pharmaceutical industry strongly urge Australian’s to seek the opinion of their prescribing doctor before discontinuing any medication as a result of information from a news outlet.

This isn’t about money, or a news article we disagree with. This is about lives, and the fact is, stopping medication suddenly, without medical oversight could have devastating consequences.

Whether deliberately or not, the ABC has conveniently forgotten to report that these life-changing medicines are approved by the regulator, available on the Pharmaceutical Benefits Scheme and comply with each and every mechanism to ensure they provide an acceptable balance between their effectiveness and safety, that they are reliable and prescribed in an appropriate and ethical manner by a doctor.

Further, these products, as with every medicine listed on the Pharmaceutical Benefits Scheme, have been subjected to years of research and development, peer review, regulatory review, numerous clinical trials and government regulations.

For example, the National Health and Medical Research Council, Pharmaceutical Benefits Advisory Committee (PBAC), Therapeutic Goods Administration (TGA), and NPS Medicine Wise all have clear guidelines relating to the approval of pharmaceutical use in Australia.

In addition to these measures, the TGA requires pharmaceutical companies to provide product education to medical practitioners. The idea that a medical practitioner would forgo their years of training and ethical obligations to patients at the behest of a pharmaceutical representative or because of support to attend a medical conference is preposterous.

Casting aspersions about the integrity of medical practitioners does nothing but undermine patient confidence at a time when there is already so much conflicting information surrounding medicines and appropriate treatments which is so readily available through “Dr Google” and Facebook.

The ABC must surely consider the possibility that people will, despite their ineffective warning at the end of the printed-only articles, stop taking these important medicines.

The ABC has some experience with this. In 2013, the ABC published a similarly salacious story on Statins. In that story, they alleged that there actually wasn’t all that much of a link between high cholesterol and heart disease, and that people were taking medications to prevent cardiac events needlessly.

The widely criticised program — removed from the ABC’s website a year ago after it was found to have breached the broadcaster’s impartiality standards — had an immediate impact, with 14,000 fewer people dispensed statin medications after the series went to air in October 2013, the University of Sydney’s Faculty of Pharmacy study found. In the months following the debunked broadcast, an estimated 60,897 fewer people filled their statins prescriptions, found the study, published in The Medical Journal of Australia.

This time around, we would have hoped that the ABC had learnt their lesson. Instead, there’s the very real potential that they have caused more harm than good.

Pharmaceutical companies and medical professionals share an important partnership. We collaborate on clinical research, share knowledge and support education to ensure that medicines are constantly improving and are used safely and appropriately by doctors and their patients.

Our member companies are committed to transparency in their interactions with medical professionals and regularly publicly report on them. The Medicines Australia Code of Conduct is the national standard for industry self-regulation and is leading the way on transparency. This Code has the approval of the ACCC.

Regarding the novel Anti-coagulants featured in the story, and the claims that our members were influencing medical practitioners, Medicines Australia has twice provided a statement to the ABC, in December and January, refuting their unsubstantiated claims. We also provided them with links to the relevant prescribing and education guidelines by the TGA.

Given ABC’s previous experience, Medicines Australia had high hopes the ABC would be a little more balanced in their reporting and consider the effects of urging people not to take their life-saving medications.

More information – Natalie Wimmer – Communications Manager, Medicines Australia – 0450728660

MA Welcomes Labor’s Better Budgeting discussion paper

MA Welcomes Labor’s Better Budgeting discussion paper

Medicines Australia, the industry association for the innovative pharmaceuticals industry welcomes Labor’s Better Budgeting discussion paper released today.

Medicines Australia Chief Executive Milton Catelin said: “Labor has asked a number of key questions that warrant careful examination.”

“One of the major public policy challenges is how to ensure Australians continue to receive world-class healthcare that improves lives and boosts the economy while also maintaining Budget rigour and fiscal sustainability,” Mr Catelin said.

“We entirely agree with the proposition that best outcomes in public policy emerge when the budget process is open, accountable, and transparent,” he said.

“How Australia’s healthcare system is managed, including the Pharmaceutical Benefits Scheme (PBS), is a key factor in Australia’s future. Research shows that medicines help to reduce expenditure elsewhere in the health system by keeping people healthy, reducing their stay in hospitals or preventing other more expensive treatments.”

Medicines Australia’s pre-budget submission argues for the inclusion of better productivity measures as part of Australia’s long-term research and data programme.

In its submission, Medicines Australia also outlines the need for clearer and more transparent information about PBS expenditure.

“These changes would significantly enhance the way in which the impact of health expenditure can be evaluated by policy-makers,” Mr Catelin said.

“We are actively engaged in policy debate about better budgeting and look forward to consulting with Labor following the release of this important paper.”

CONTACT: Natalie Wimmer – Communications Manager – 0450728660

AIHW results validate MA findings

AIHW results validate MA findings

The Australian Institute of Health and Welfare’s (AIHW) latest report Cancer in Australia 2017, is a welcome validation of the importance of pharmaceutical innovation for cancer survival rates.

The report shows that while cancer is a major cause of ill health in Australia, and more cases are being diagnosed, death rates have continued to fall since the 1980s, and incidence rates have also decreased in recent years.

The report estimates that over 134,000 new cases of cancer will be diagnosed in Australia in 2017- an average of 367 diagnoses each day and 2.8 times as high as in 1982.

The findings is a significant indicator of the value of investment in preventative health and innovative medical interventions. Its data backs up a recent study commissioned by Medicines Australia that identified that listing innovative medicines on the PBS had a significant impact on cancer survival rates.

In a report commissioned by Medicines Australia in 2015, American health economist Professor Frank Lichtenberg also estimated how medicines listed on the PBS affected cancer survival. The five year survival rate for all cancers in Australia increased from 49% to 62% between 1986 and 2007. An estimated 40% of this improvement is the result of new medicines listed on the PBS. In the absence of new medicines, the five-year survival rate would have been 57% in 2007.

Medicines Australia Chief Executive Milton Catelin commended AIHW on its critical research.

“Modelling such as that undertaken by AIHW and Medicines Australia identifies just how important it is to invest in a strong health system and the listing innovative medicines on the PBS plays a fundamental role in that,” said Mr Catelin.

“Research shows that investing in innovative medicines not only improved lives it makes the economy more productive and actually delivers significant savings in overall health costs, especially in our hospitals.”

“How Australia’s healthcare system is managed, including the Pharmaceutical Benefits Scheme (PBS), is a key factor in Australia’s future and this report should provide the Government with further validation that listing innovative medicines on the PBS is an astute investment, particularly when you think about the productivity and economic gains associated with improving health outcomes,” he said.

ENDS

CONTACT: Natalie Wimmer – Communications Manager – 0450728660

MTPConnect and Medicines Australia sign MoU to boost Australia’s innovative medicines sector

MTPConnect and Medicines Australia sign MoU to boost Australia’s innovative medicines sector

Monday, 23 January 2017, AustraliaMTPConnect – the Medical Technologies, Biotechnologies and Pharmaceuticals Industry Growth Centre – and Medicines Australia – the membership organisation representing the discovery-driven pharmaceutical industry in Australia – have signed a memorandum of understanding (MoU) to work collaboratively to boost the innovative pharmaceutical industry in Australia.

The collaboration will see the two organisations combining their efforts to champion a sector-led approach to accelerate the growth of the ecosystem, through activities to unify and educate the medical technology, biotechnology, and pharmaceutical (MTP) sector, as well as engage with government to create a positive regulatory environment.

Together, MTPConnect and Medicines Australia will support the innovative medicines and vaccines industry to:

  • Develop priorities in areas of competitive advantage that relate to the MTP sector;
  • Identify opportunities for organisations within the sector to collaborate on R&D by pooling and sharing resources;
  • Showcase the extraordinary talent of the people that work with our industry; and,
  • Partner with the Australian Government to enable this sector to thrive and lead economic repair.

Sue MacLeman, Chief Executive Officer of MTPConnect, said, “Medicines Australia is an important advocate and resource for the Australian pharmaceuticals industry. By signing an MoU with Medicines Australia, MTPConnect is excited to combine our efforts achieve our common goal of guiding Australia to realise its full potential as a world leader in the sector.

“The newly released MTPConnect Sector Competitiveness Plan – a 10-year strategic plan to boost the innovation, productivity and competitiveness of Australia’s medical technology, biotechnology, and pharmaceutical sector – addresses key issues such as collaboration and regulatory impediments. Through forging important partnerships such as this one, we are taking the first steps forward to achieve our shared visions of transforming Australia into an MTP hub that will deliver innovative and world-leading healthcare.”

Milton Catelin, Medicines Australia Chief Executive said, “The opportunity to work closely with MTPConnect will help our industry to focus on our global competitiveness.”

“This partnership will help to ensure the clinical trials environment in Australia is world leading and brings benefits to the Australian community be offering early access to medicines.”

“Our aim is to address key impediments to competitiveness within our sector. By overcoming the obstacles that impede the translation of research and development into market-ready medicines and vaccines, we keep Australians out of hospitals, prevent disease, boost productivity and the economy.”

“MA also looks forward to working with MTPConnect to identify opportunities to address regulations that are unnecessary or overly burdensome that impede growth of this important industry.”>

-ENDS-

About MTPConnect

MTPConnect was formed as a not-for-profit organisation in November 2015 as part of the federal government’s $250 million Industry Growth Centres Initiative to accelerate the rate of growth of the MTP sector, achieve greater commercialisation and establish Australia as an Asia-Pacific hub for MTP companies.

The MTPConnect Head Office is located at the New Horizons Building at Monash University, co-located with CSIRO and industry. There are also key hubs at the University of Sydney’s Institute of Biomedical Engineering and Technology and the Medical Device Research Institute at Flinders University at Tonsley in Adelaide.

About Medicines Australia

Medicines Australia represents the innovative medicines and vaccines industry in Australia. Our member companies discover, invent, manufacture and supply innovative medicines and vaccines to the Australian community. Those medicines keep Australians out of hospitals, prevent disease and play a pivotal role in ensuring a productive and healthy community.

Medicines Australia drives the creation and development of a predictable environment for the continued, sustainable growth of the innovative and research-based prescription medicines industry so that Australians can continue to lead longer and healthier lives.

Media inquiries:

Zoe Stephenson
Corporate Communications Manager, MTPConnect
+61 3 9905 1757
zoe.stephenson@mtpconnect.org.au

Natalie Wimmer
Communications Manager, Medicines Australia
0450 728 660
Natalie.Wimmer@medicinesaustralia.com.au

Medicines Australia welcomes new appointments to Health and Industry portfolios

Medicines Australia welcomes new appointments to Health and Industry portfolios

Medicines Australia Chief Executive, Mr Milton Catelin, has welcomed the appointment of the Hon Greg Hunt MP as the new Minister for Health and Minister for Sport.

“I congratulate Minister Hunt on his appointment to a portfolio that has an enormous impact on the health and wellbeing of all Australians and the Australian economy,” Mr Catelin said.

“This important industry welcomes the opportunity to collaborate with Minister Hunt and his office to ensure that we continue to develop a no-surprises environment that maintains the viability of the medicines industry in Australia and timely access to medicines for Australian patients.”

“As the peak body representing the innovative pharmaceutical industry in Australia, Medicines Australia will be able to offer the new Minister detailed advice on the contribution that innovative medicines make to the Australian community and economy.”

“Minister Hunt has worked well previously with the sector as Minister for Industry, Innovation & Science, and understands the industry’s issues including the need to nurture a strong, sustainable Pharmaceutical Benefits Scheme (PBS).”

Minister Hunt has a track record as being an effective minister who engages closely with all stakeholders to ensure that he is getting efficient and practical outcomes for issues that relate to his recent portfolios.

“I look forward to working with Minister Hunt as he works toward completing the Medicines and Medical Devices Regulation reforms, Clinical Trial reforms, as well as achieving faster approval processes for innovative medicines and ensuring our members get stability and certainty as we lead into this year’s Budget.”

Medicines Australia also congratulates Senator Hon Arthur Sinodinos on assuming the role of Minister for Industry, Innovation & Science, who has a long history of support for the medical science community.

“Our industry strongly depends on scientific advancement and research innovation, and we look forward to continuing to work with Senator Sinodinos in this respect,” said Mr Catelin.

Medicines Australia and its member’s would also like to acknowledge the Hon Ken Wyatt MP on becoming the Minister for Aged Care and Minister for Indigenous Health and note that he is first indigenous Australian to be appointed to the Ministry.

The industry would also like to congratulate Senator the Hon Scott Ryan and Mr Michael Sukkar MP on their elevations.

“Medicines Australia and our members look forward to an ongoing and constructive relationship with the PM and his team,” said Mr Catelin.

Contact:

Natalie Wimmer
Phone: (02) 6122 8500
Email:
 Natalie.Wimmer@medicinesaustralia.com.au

Seeking: Thought Leaders: New Advisory Council to Medicines Australia

Seeking: Thought Leaders: New Advisory Council to Medicines Australia

Medicines Australia (MA) is the peak body representing the innovative medicines and vaccines industry. It is committed to delivering a longer and healthier life for all Australians through availability and choice of world leading innovative medicines and development of a sustainable research-based prescription medicines industry. Its members are companies that invent, manufacture, export and supply innovative medicines and vaccines to Australians and the world.

The future focussed Advisory Council will provide the Board with strategic advice on trends and issues impacting the Industry in the medium to long term (3 to 10 years). This advice will inform the Board in setting the future strategic priorities for Medicines Australia and the innovative medicines and vaccines industry more broadly.

If you are passionate about shaping the future of this vital industry, please review the Medicines Australia’s Advisory Council Candidate Kit and apply.

Applications should be forwarded to Advisory.Council@medicinesaustralia.com.au no later than 5pm Monday 13th February, 2017.

Confidential enquiries and applications should be addressed to Dee Hopkins at Medicines Australia either by email or call (02) 6122 8560 or 0419 012 094.

Productivity Commission’s Report Recommendations Would Hurt Australian Innovation and Delay Access to Breakthrough Medicines

Productivity Commission’s Report Recommendations Would Hurt Australian Innovation and Delay Access to Breakthrough Medicines

The Productivity Commission report recommendations, if adopted, would put local jobs, investment and Australian patients’ early access to breakthrough medicines at risk.

The Commission continues to misunderstand the value of Intellectual Property (IP) and is putting at risk the jobs of thousands of Australian scientists and medical researchers, as well as sending a signal to investors that Australia is indeed “closed for business”.

These recommendations, if implemented, would undermine the Government’s Innovation Agenda, particularly in the Medical Research sector, including local biotechnology companies.

These recommendations would also see Australia’s competitiveness fall even further behind other countries with more robust IP systems such as those in the UK, Japan and Europe. Medical Research is one of the few sectors identified by the Government as having the potential to grow our economy into the medium term.

IP is critical to secure new and better treatments for patients – it takes 15+ years of expensive R&D to bring forward new innovation in medical science. Watering down Australia’s existing IP regime puts at risk early access to medical innovation by Australians as it will become unviable to bring a new product directly to market in Australia.

The proposed reform of Australia’s IP regime also sends a troubling signal to our members who currently invest $1 billion a year in local R&D.

The report findings are also at odds with the Australian Government’s efforts to attract more clinical trials which give patients free, fast access to the latest medicines in the final phases of development.

We welcome the Government’s consultation process and hope that they will dismiss the recommendations in this report that risk losing investment and jobs in this critical sector. We look forward to continuing this vital work with the Australian Government to ensure Australia has a thriving environment for research and development.

Contact:

Natalie Wimmer
Phone: (02) 6122 8500
Email:
 Natalie.Wimmer@medicinesaustralia.com.au

New member appointees to the Medicines Australia Board

New member appointees to the Medicines Australia Board

The Chairman of Medicines Australia, Mr Wes Cook, would like to announce that Melissa McGregor and Bruce Goodwin have been voted to the Board of Directors.

Melissa McGregor is the Managing Director of Pfizer in Australia & New Zealand, while Bruce Goodwin is the Managing Director of Janssen Pharmaceuticals in Australia and New Zealand (a subsidiary of Johnson & Johnson).

Their appointments follow the recent departures of Geoff McDonald (GSK) and James Priour (Amgen) from the Board. Both appointees will hold their positions until the next Annual General Meeting, to be held in October 2017, when all Board positions will be up for nomination.

Mr Goodwin previously served on the Medicines Australia Board between 2009 and 2012. He also served for two years as the Vice-Chairman of the Japanese-based executive committee of PhRMA while working as President of Janssen in Japan.

Ms McGregor was a Board member of the New Zealand industry body when she was recently running Pfizer’s local operations.

“On behalf of the membership, I would like to congratulate both Melissa and Bruce on their successful nominations to the Medicines Australia Board,” said Mr Cook.

“To be nominated by your peers to represent the industry is a tremendous honour and I know both Bruce and Melissa will be valuable additions to the Board.”

“Combined, they bring five decades worth of experience in the pharmaceutical industry with much of that time in Australia.”

“Their experience in the sector will help them to play a vital role in the policy discussions that are critical to our members.”

“I look forward to working alongside Melissa and Bruce during what will be an important year for our industry,” said Mr Cook.

Medicines Australia Chief Executive, Milton Catelin said, “to have a strong members’ organisation you need a strong Board of Directors and Melissa and Bruce will not only meet that challenge they will help further strengthen the reputation of this important industry.”

“I have no doubt that I will be utilising their insights and experience as we meet the policy challenges over the year ahead.”

“On behalf of Medicines Australia I would like to congratulate them both on their appointments.”

Ms McGregor and Mr Goodwin will participate in their first Board meeting in February 2017.

Contact:

Natalie Wimmer
Phone: (02) 6122 8500
Email:
 Natalie.Wimmer@medicinesaustralia.com.au

Former AusBiotech CEO appointed to Medicines Australia Board as Independent Director

Former AusBiotech CEO appointed to Medicines Australia Board as Independent Director

Medicines Australia has appointed Dr Anna Lavelle as an independent Board member following a comprehensive recruitment process.

The appointment follows her recent retirement from AusBiotech where she served for eleven years as the CEO of the industry association which represents Australia’s growing biotechnology sector.

Medicines Australia Chairman Mr Wes Cook said: “Dr Lavelle is a talented, well respected person within the innovative pharmaceutical and biotechnology sector who will now bring her years of experience to our Board.”

“For more than 25 years, Dr Lavelle has served on the boards of not-for-profit, government and for-profit entities.”

“Dr Lavelle is well known to all of our members and already has a reputation as an industry leader and trusted advisor.”

“She has strong governance skills and has a lengthy track record in healthcare delivery, technology development and government policy.”

“As the independent Board member, Dr Lavelle will play a critical role in Board governance but is also well qualified to provide advice to the Board and our members on relevant policy issues for our sector,” Mr Cook said.

Chief Executive Milton Catelin said, “I want to congratulate Dr Lavelle on this important appointment and I look forward to working closely with her in the months ahead.”

“I would also like to thank all of those who applied for the Independent Director role. There were many talented, experienced applicants which is a wonderful sign of the high regard there is for this important industry,” said Mr Catelin.

Dr Lavelle will also Chair the soon to be created Medicines Australia Advisory Council which will be made up of senior leaders from the membership as well as leaders from the broader health science sector.

An announcement of the Advisory Council appointees will be made early in the New Year.

Contact:

James Boyce
Phone: 0423 239 265
Email:
 James.Boyce@medicinesaustralia.com.au

Medicines Australia Member To Play A Crucial Role In The Biomedical Translation Fund

Medicines Australia Member To Play A Crucial Role In The Biomedical Translation Fund

Medicines Australia welcomes today’s announcement that CSL Limited will be a co-investor in the Government’s Biomedical Translation Fund (BTF) which has been developed to stimulate investment in commercialising Australian medical science.

This co-investment will form part of a fund called the Medical Research Commercialisation Fund Biomedical Translation Fund (MRCF BTF) which will see $115 million of public funds matched by $115 million of private investment.

Medicines Australia CEO Milton Catelin said, “This partnership is recognition that scientific innovation is a key driver of economic growth and the creation of jobs for Australians.”

“CSL Limited (a Medicines Australia member company) is a well-known Australian-grown medicines and vaccines developer at the forefront of medical science and its decision to be a co-investor is good news not just for our sector but for Australia’s medical research community.”

“CSL Limited are to be congratulated on their commitment to driving the research agenda in Australia,” said Mr Catelin.

Funded as part of the National Innovation and Science Agenda, the BTF is designed to ensure the most promising Australian research discoveries have access to institutional growth capital needed for them to be turned into better medical products and services.

In its entirety, there will be $250 million investment in the BTF fund from the Government to be dollar-matched by private sector co-investment.

“It’s critical that our government continue to foster a culture where innovation policies help to stimulate Australia’s capabilities to facilitate the next generation of breakthrough medicines, said Mr Catelin.

“If managed appropriately, the BTF, including the MRCF BTF, have the capacity to vastly improve the lives of average Australians. It will see the creation of new jobs – particularly in STEM areas – that will help Australia compete as global players in innovation, science and the delivery of life-changing technology.”

“Our members already deliver more than $1 billion every year to Australian research and development and the more our politicians deliver policies which encourage innovation like the BTF, the more this important sector will evolve.”

“Medicines Australia congratulates the Australian Government for driving this innovation and research agenda.”

Contact:

James Boyce
Phone: 0423 239 265
Email:
 James.Boyce@medicinesaustralia.com.au